BioVie (BIVI)

• Market cap: $20.8M
• 1 day: -4.20%
• 5 days: 3.64%
• 1 month: 6.54%
• 3 months: 11.76%
• 6 months: -56.82%
• Year to date: -47.71%
• 1 year: -76.54%
• 5 years: -98.86%
• 10 years: -98.86%
• Sector: Healthcare
• Industry: Biotechnology

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 14

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

1.11% more ownership

Funds ownership: 4.26% [Q4 2024] → 5.36% (+1.11%) [Q1 2025]

14% less funds holding

Funds holding: 43 [Q4 2024] → 37 (-6) [Q1 2025]

36% less capital invested

Capital invested by funds: $1.52M [Q4 2024] → $968K (-$550K) [Q1 2025]

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10